CLARITY PHARMACEUTICALS LTD — Investor Relations & Filings

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company focused on developing next-generation products to improve treatment outcomes for children and adults with cancer. The company utilizes its proprietary SAR Technology platform, which employs highly stable chelators to link copper isotopes to targeting molecules. This platform supports a Targeted Copper Theranostics (TCT) approach, pairing Copper-64 for high-resolution PET imaging with Copper-67 for targeted radiotherapy. Key pipeline assets include SAR-bisPSMA for prostate cancer, SAR-Bombesin for various solid tumors, and SARTATE for neuroblastoma and neuroendocrine tumors. By leveraging the physical properties of copper isotopes, the company aims to overcome logistical and manufacturing limitations associated with traditional radiopharmaceuticals, enabling centralized distribution and broader patient access to precision oncology treatments.